Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

BCL2L1 remained highly expressed and showed a trend toward upregulation in HSPCs of post-MPN AML ( Figure 2 A; P = .052), and BCL2 expression was increased ( Figure 2 B; P = .0049).

also in 53,322 other papers